Sven‐Erik Dahlén

19.0k citations

214 papers · 12.4k indexed · 6 hit papers · h-index 49

Immunology and Allergy top 0.2%
- Allergic Rhinitis and Sensitization 45
Physiology top 0.1%
- Asthma and respiratory diseases 149
Biochemistry top 0.1%
- Eicosanoids and Hypertension Pharmacology 18
Immunology top 0.5%
- Mast cells and histamine 30
Pharmacology top 0.2%
- Inflammatory mediators and NSAID effects 27
Pulmonary and Respiratory Medicine
- Respiratory and Cough-Related Research 54
- Inhalation and Respiratory Drug Delivery 17
- Chronic Obstructive Pulmonary Disease (COPD) Research 16

Co-authors: Bengt Samuelsson Per Hedqvist Charles N. Serhan Jan Lindgren Sven Hammarström Carol A. Rouzer Barbro Dahlén Maria Kumlin
Cited by: Immunology and Allergy Physiology Biochemistry
Partner nations: Sweden United States United Kingdom

In The Last Decade

Sven‐Erik Dahlén

206 papers receiving 11.9k citations

Hit Papers

6 papers align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2024 Airway hyperresponsiveness in asthma: The role of the epithelium
2012 Differential DNA Methylation in Purified Human Blood Cells: Implications for Cell Lineage and Studies on Disease Susceptibility
1987 Leukotrienes and Lipoxins: Structures, Biosynthesis, and Biological Effects
1981 Identification and biological activity of novel ω‐oxidized metabolites of leukotriene B₄ from human leukocytes
1981 Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary venules: in vivo effects with relevance to the acute inflammatory response.
1980 Leukotrienes are potent constrictors of human bronchi

Peers

Countries citing papers authored by Sven‐Erik Dahlén

Since Specialization

Citations

This map shows the geographic impact of Sven‐Erik Dahlén's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sven‐Erik Dahlén with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sven‐Erik Dahlén more than expected).

Fields of papers citing papers by Sven‐Erik Dahlén

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sven‐Erik Dahlén. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sven‐Erik Dahlén. The network helps show where Sven‐Erik Dahlén may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Sven‐Erik Dahlén, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Sven‐Erik Dahlén Line = papers co-authored together Sven‐Erik Dahlén links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Treatable traits in asthma associated with hospitalisations Marina Labor,Christer Janson,Andreas Palm,Andreï Malinovschi,Mathias Holm,Linda Ekerljung,Sven‐Erik Dahlén,Lars Modig,Össur Ingi Emilsson	2025	0
2	Airway hyperresponsiveness in asthma: The role of the epitheliumbreakdown → Peter Bradding,Celeste Porsbjerg,Andréanne Côté,Sven‐Erik Dahlén,Teal S. Hallstrand,Christopher E. Brightling	2024	49
3	Proteomic signatures of eosinophilic and neutrophilic asthma from serum and sputum Khezia Asamoah,Kian Fan Chung,Nazanin Zounemat Kermani,Barbara Bodinier,Sven‐Erik Dahlén,Ratko Djukanović,Pankaj Bhavsar,Ian M. Adcock,Dragana Vuckovic,Marc Chadeau‐Hyam	2023	15
4	Effects of non‐steroidal anti‐inflammatory drugs and other eicosanoid pathway modifiers on antiviral and allergic responses: EAACI task force on eicosanoids consensus report in times of COVID‐19 Milena Sokołowska,G. Enrico Rovati,Zuzana Diamant,Eva Untersmayr,Jürgen Schwarze,Zuzanna Łukasik,Florentina Sava,Alba Angelina,Óscar Palomares,Cezmi A. Akdiş,Liam O’Mahony,Miloš Jeseňák,Oliver Pfaar,Marı́a José Torres,Marek Sanak,Sven‐Erik Dahlén,Grzegorz Woszczek	2022	13
5	Treating severe asthma: Targeting the IL‐5 pathway Stefania Principe,Celeste Porsbjerg,Sisse B. Ditlev,Ditte Kjærsgaard Klein,Korneliusz Golebski,Nanna Dyhre‐Petersen,Yoni E. van Dijk,Job J.M.H. van Bragt,Lente L.H. Dankelman,Sven‐Erik Dahlén,Christopher E. Brightling,Susanne J. H. Vijverberg,Anke H. Maitland‐van der Zee	2021	47
6	Selective inhibition of prostaglandin D₂ biosynthesis in human mast cells to overcome need for multiple receptor antagonists: Biochemical consequences Anna‐Karin Johnsson,Jeong‐Hee Choi,Elin Rönnberg,David Fuchs,Johan Kolmert,Mats Hámberg,Barbro Dahlén,Craig E. Wheelock,Sven‐Erik Dahlén,Gunnar Nilsson	2021	8
7	Current perspective on eicosanoids in asthma and allergic diseases: EAACI Task Force consensus report, part I Milena Sokołowska,G. Enrico Rovati,Zuzana Diamant,Eva Untersmayr,Jargen Schwarze,Zuzanna Łukasik,Florentina Sava,Alba Angelina,Óscar Palomares,Cezmi A. Akdiş,Liam O’Mahony,Marek Sanak,Sven‐Erik Dahlén,Grzegorz Woszczek	2020	45
8	Leukotriene receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database Magnus Bäck,Charles Brink,Nan Chiang,Sven‐Erik Dahlén,Gordon Dent,Jeffrey M. Drazen,Jilly F. Evans,Douglas W.P. Hay,Motonao Nakamura,William S. Powell,Joshua Rokach,G. Enrico Rovati,Charles N. Serhan,Takao Shimizu,Takehiko Yokomizo	2019	1
9	Leukotriene E4 induces airflow obstruction and mast cell activation through the cysteinyl leukotriene type 1 receptor Nikolaos Lazarinis,Johan Bood,Cristina Gómez,Johan Kolmert,Ann‐Sofie Lantz,Pär Gyllfors,Andy Davis,Craig E. Wheelock,Sven‐Erik Dahlén,Barbro Dahlén	2018	35
10	Quality of life in relation to the traffic indicators NO2 and NOx: Results from the Swedish GA2LEN survey Bertil Forsberg,Johan Nilsson Sommar,Alexandra Ek,Sven‐Erik Dahlén,Roelinde Middelveld,Anders Bjerg,Helén Bertilsson,Linda Ekerljung,Andreï Malinovschi,Christer Janson,(unknown)	2013	1
11	Transcriptome analysis reveals upregulation of bitter taste receptors in severe asthmatics Christina Orsmark‐Pietras,Anna James,Jon R. Konradsen,Björn Nordlund,Cilla Söderhäll,Ville Pulkkinen,Christophe Pedroletti,Kameran Daham,Maciej Kupczyk,Barbro Dahlén,Juha Kere,Sven‐Erik Dahlén,Gunilla Hedlin,Erik Melén	2012	128
12	Which anti-inflammatory drug should we use in asthma? Maciej Kupczyk,Barbro Dahlén,Sven‐Erik Dahlén	2011	6
13	Improvement of Aspirin-Intolerant Asthma by Montelukast, a Leukotriene Antagonist: A Randomized, Double-Blind, Placebo-Controlled Trial Sven‐Erik Dahlén,Kerstin Malmström,Ewa Niżankowska,Barbro Dahlén,Piotr Kuna,Marek Kowalski,William R. Lumry,César Picado,Donald D. Stevenson,Jean Bousquet,Romain Pauwels,Stephen T. Holgate,Aditi Shahane,Ji Zhang,Theodore F. Reiss,A Szczeklik	2002	236
14	Pulmonary Gas Exchange and Sputum Cellular Responses to Inhaled Leukotriene D4 in Asthma Andrés L. Echazarreta,Barbro Dahlén,Gabriel García,Carlos Agustı́,Joan Albert Barberà,Josep Roca,Sven‐Erik Dahlén,Robert Rodriguez-Roisín	2001	31
15	Leukotrienes as Targets for Treatment of Asthma and Other Diseases: Current Basic and Clinical Research Sven‐Erik Dahlén,Jesper Z. Haeggström,Bengt Samuelsson,Klaus F. Rabe,Alan R. Leff	2000	19
16	Pharmacological Characterization of Leukotriene Receptors Sven‐Erik Dahlén	2000	35
17	Benefits from Adding the 5-Lipoxygenase Inhibitor Zileuton to Conventional Therapy in Aspirin-intolerant Asthmatics Barbro Dahlén,Ewa Niżankowska,A Szczeklik,O. Zetterström,Grażyna Bochenek,Maria Kumlin,Lucyna Mastalerz,Grazyna Pinis,Linda J. Swanson,Terry Boodhoo,Stephen Wright,Louise M. Dubé,Sven‐Erik Dahlén	1998	291
18	Combined Antagonism of Leukotrienes and Histamine Produces Predominant Inhibition of Allergen-Induced Early and Late Phase Airway Obstruction in Asthmatics A. Roquet,Barbro Dahlén,Maria Kumlin,E. Ihre,Gudrun Anstrén,S Binks,Sven‐Erik Dahlén	1997	235
19	Delayed anti-inflammatory action of nedocromil sodium in the rat paw is dependent on de novo protein synthesis Johan Raud,David B. Konrad,Sven‐Erik Dahlén	1995	5
20	Leukotrienes and Other Eicosanoids as Mediators of Airway Obstruction Sven‐Erik Dahlén,Maria Kumlin,Elisabeth Granström,Per Hedqvist	1986	16

About Sven‐Erik Dahlén

Sven‐Erik Dahlén is a scholar working on Immunology and Allergy, Physiology and Biochemistry, having authored 214 papers that have together received 12.4k indexed citations. Recurring topics across this work include Asthma and respiratory diseases (149 papers), Respiratory and Cough-Related Research (54 papers), Allergic Rhinitis and Sensitization (45 papers), Mast cells and histamine (30 papers), Inflammatory mediators and NSAID effects (27 papers), Eicosanoids and Hypertension Pharmacology (18 papers), Inhalation and Respiratory Drug Delivery (17 papers) and Chronic Obstructive Pulmonary Disease (COPD) Research (16 papers). The work is most often cited by research in Immunology and Allergy (1.8k citations), Physiology (5.9k citations) and Biochemistry (1.3k citations). Sven‐Erik Dahlén has collaborated with scholars based in Sweden, United States and United Kingdom. Frequent co-authors include Bengt Samuelsson, Per Hedqvist, Charles N. Serhan, Jan Lindgren, Sven Hammarström, Carol A. Rouzer, Barbro Dahlén, Maria Kumlin, T Björck and J A Lindgren.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact